Combined modality therapy for stage II and stage III pancreatic carcinoma.

Kamthan, A; Morris, John C.; Dalton, Jack; Mandeli, John; Chesser, Margaret R.; Leben, Dvora; Cooperman, Avram M.; Bruckner, Howard W.

doi:10.1200/jco.1997.15.8.2920

Cited by 95 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent trials of preoperative chemoradiation have been conducted at Fox Chase Cancer Center (including the Eastern Cooperative Oncology Group phase II trial), 26 -29 The M. D. Anderson Cancer Center, 7,30,31 New England Deaconess/Dartmouth Medical Centers, 32,33 Roger Williams Cancer Center, 34,35 and the Mount Sinai Hospital. 36 While employing different regimens of chemotherapy and radiotherapy (including intraoperative radiotherapy at M.D. Anderson), these trials have each reported surgical complication and mortality rates similar to those of patients without preoperative treatment and lower rates of local recurrence.…”

Section: Discussionmentioning

confidence: 98%

Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas

et al. 1999

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Response rates varied between 39% and 47%, with a median survival time of 14-15.5 months [4,[30][31][32]. The resectability rate was 10.5%, using combined radiochemotherapy with 5-FU, leucovorin, and mitomycin [30], and 14.2% after 5-FU, streptozotocin, and cisplatin, with simultaneous split-course radiotherapy [4].…”

Section: Discussionmentioning

confidence: 99%

Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer

Epelbaum

Rosenblatt

Nasrallah

et al. 2002

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Based on the high rate of recurrence, surgery alone seems to be inadequate for the treatment of patients with pancreatic cancer. Indeed, new clinical approaches such as, for example adjuvant chemotherapy plus radiation therapy (chemoradiation) after surgery or before surgery have been attempted and only a little improvement was observed in the survival rates of patients with pancreatic cancer, but the prognosis has remained worse than other cancers, such as breast cancer, colon cancer and gastric cancer (Ozaki et al, 1996;Schnall et al, 1996;Kamthan et al, 1997). In addition, most patients with pancreatic cancers are already unresectable when they are initially diagnosed.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of angiogenesis in human pancreatic cancer

et al. 1999

View full text Add to dashboard Cite

To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%) were evaluated to be PD-ECGF -positive and 10 carcinomas (25.0%) were determined to be PD-ECGF -negative. In contrast, 27 carcinomas (67.5%) were evaluated to be VEGF -positive, whereas 13 carcinomas (32.5%) were VEGF -negative. VEGF gene expression was moderately associated with an increase in the IMD ( r 2 = 0.181, P = 0.006), but no significant relationship was found between PD-ECGF gene expression and the IMD ( r 2 = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF had a higher IMD ( P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median survival time of the hypervascular group was significantly shorter than that of the hypovascular group ( P < 0.0001). In comparing the survival according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was significantly shorter than those with negative PD-ECGF expression ( P = 0.040). Furthermore, the median survival time of the patients with positive VEGF expression was significantly shorter than those with negative VEGF expression ( P = 0.048). However, the Cox multivariate analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in pancreatic cancer patients ( P = 0.0021 and P = 0.0443, respectively). © 1999 Cancer Research Campaign

show abstract

Combined modality therapy for stage II and stage III pancreatic carcinoma.

Abstract: Palliation and survival compare favorably with other series, including many surgical series. The response findings encourage studies of both unresectable and (as neoadjuvant therapy) resectable tumors.

Cited by 95 publications

References 30 publications

Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas

Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas

Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer

Prognostic significance of angiogenesis in human pancreatic cancer

Contact Info

Product

Resources

About